2025-06-09-花旗集团-花旗最受关注-医疗保健_11页_182kb

报告摘要

Citi Healthcare Super-Sector Analysis Summary

Citi Research's Healthcare Super-Sector encompasses Pharmaceuticals & Biotechnology, Medical Services, Medical Supplies, Medical Technology, and Life Sciences sectors. Recent research highlights disruptions and innovation opportunities across these areas.

European Healthcare Services and MedTech

MedTech has underperformed the EuroSTOXX due to concerns like tariffs and FX headwinds.
Valuations are near historical averages, with resilience in Q1 2025.
Opportunities emerge amid uncertainty; key recommendations include upgrades to Demant (Buy) and a constructive view on the sector overall, reducing Sells to 3 and increasing Buys to 11.

US Biotechnology and Pharmaceuticals

Coverage focuses on biopharma innovation, obesity treatments (e.g., tirzepatide, orforglipron), and neuroscience.
Policy risks remain, but structural growth drivers and turnaround stories are prioritized.
Eli Lilly remains a Buy with a $1,190 target; Merck's oncology portfolio is highlighted, but long-term Keytruda exposure is a concern (Neutral, $84 target).
Conferences like Napa and ADA provide insights into drug launches and commercial profiles.

European Life Science Tools & Diagnostics

Tools companies face regulatory and budget uncertainties but have growth potential (e.g., PFAS).
Product updates are minimal, but personalization strategies are gaining traction.

Company-Specific Insights

Hims & Hers Health: Acquiring ZAVA expands European footprint and accelerates personalization.
MoonLake Immunotherapeutics: Acquisition interest from Merck drives stock rise; sonelokimab shows potential.
ResMed: Reiterated Buy with a $45 target, maintaining attractiveness due to strong financials despite GLP-1 risks.